

**Clinicaltrials.org - Alzheimer's trials for Aduhelm, Leqembi, & Donanemab as of June 2023**

**Leqembi/lecanemab/BAN2401**

Investigator ID	#	Link	Study Start Date	Study Completion Date	Population	# participants	Age Range	Study Phase	Recruitment Status
BAN2401-I081-104	NCT02094729	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT02094729">https://classic.clinicaltrials.gov/ct2/show/NCT02094729</a>	9/1/2013	5/1/2015	MCI due to AD or Mild AD	26	50-90	Phase 1	Completed
BAN2401-G000-301	NCT03887455	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT03887455">https://classic.clinicaltrials.gov/ct2/show/NCT03887455</a>	3/27/2019	9/15/2027	Early AD	1906	50-90	Phase 3	Active, Not Recruiting
BAN2401-G000-303	NCT04468659	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT04468659">https://classic.clinicaltrials.gov/ct2/show/NCT04468659</a>	7/14/2020	10/25/2027	Preliminary AD w/ Elevated/Intermediate Amyloid	1400	55-80	Phase 3	Recruiting
BAN2401-G000-201	NCT01767311	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT01767311">https://classic.clinicaltrials.gov/ct2/show/NCT01767311</a>	12/20/2012	2/20/2025	MCI due to AD or Mild ADD	856	50-90	Phase 2	Active, Not Recruiting
BAN2401-A001-101	NCT01230853	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT01230853">https://classic.clinicaltrials.gov/ct2/show/NCT01230853</a>	8/1/2010	2/1/2013	Mild to Moderate AD	80	50-above	Phase 1	Completed
BAN2401-A001-005	NCT05533801	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05533801">https://classic.clinicaltrials.gov/ct2/show/NCT05533801</a>	9/6/2022	1/6/2023	Healthy Volunteers	160	18-65	Phase 1	Completed
BAN2401-A001-004	NCT05045716	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05045716">https://classic.clinicaltrials.gov/ct2/show/NCT05045716</a>	9/7/2021	12/7/2021	Healthy Volunteers	60	18-65	Phase 1	Completed
DIAN-TU-001	NCT05269394	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05269394">https://classic.clinicaltrials.gov/ct2/show/NCT05269394</a>	12/22/2021	10/1/2027	Asymptomatic/Early Dominantly Inherited AD	168	18-80	Phase 2/3	Recruiting
<b>Lecanemab Healthy Volunteers</b>						<b>220</b>			
<b>Lecanemab AD Patients</b>						<b>4436</b>			
<b>Lecanemab Total</b>						<b>4656</b>			

**Donanemab/LY3002813**

Investigator ID	#	Link	Study Start Date	Study Completion Date	Population	# participants	Range	Phase	Recruitment Status
I5T-MC-AACM	NCT05026866	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05026866">https://classic.clinicaltrials.gov/ct2/show/NCT05026866</a>	8/27/2021	11/8/2027	Preliminary AD	3300	65-80	Phase 3	Recruiting
I5T-MC-AACO	NCT05508789	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05508789">https://classic.clinicaltrials.gov/ct2/show/NCT05508789</a>	10/10/2022	6/11/2027	Early Symptomatic AD	1500	60-85	Phase 3	Recruiting
I5T-MC-AACI	NCT04437511	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT04437511">https://classic.clinicaltrials.gov/ct2/show/NCT04437511</a>	6/19/2020	8/22/2025	Early AD	1800	60-85	Phase 3	Active, Not Recruiting
I5T-MC-AACQ	NCT05738486	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05738486">https://classic.clinicaltrials.gov/ct2/show/NCT05738486</a>	2/28/2023	5/13/2025	Early Symptomatic AD	800	60-85	Phase 3b	Recruiting
I5T-MC-AACN	NCT05108922	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05108922">https://classic.clinicaltrials.gov/ct2/show/NCT05108922</a>	11/16/2021	7/2/2024	Early Symptomatic AD	200	50-85	Phase 3	Active, Not Recruiting
I5T-MC-AACH	NCT04640077	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT04640077">https://classic.clinicaltrials.gov/ct2/show/NCT04640077</a>	11/23/2020	3/5/2024	ENROLLS PRIOR DONANEMAB RECIPIENTS	90	60-90	Phase 2	Active, Not Recruiting
I5T-MC-AACP	NCT05567159	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05567159">https://classic.clinicaltrials.gov/ct2/show/NCT05567159</a>	10/4/2022	7/14/2023	Healthy Volunteers	30	18-40	Phase 1	Completed
I5T-MC-AACK	NCT05533411	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05533411">https://classic.clinicaltrials.gov/ct2/show/NCT05533411</a>	9/14/2022	1/5/2023	Healthy Volunteers	36	18-40	Phase 1	Completed
I5T-MC-AACG	NCT03367403	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT03367403">https://classic.clinicaltrials.gov/ct2/show/NCT03367403</a>	12/18/2017	9/21/2021	Early Symptomatic AD	272	60-85	Phase 2	Completed
I5T-MC-AACD	NCT02624778	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT02624778">https://classic.clinicaltrials.gov/ct2/show/NCT02624778</a>	12/22/2015	8/28/2019	MCI due to AD or Mild/Moderate AD	61	50-above	Phase 1	Completed
I5T-MC-AACC	NCT01837641	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT01837641">https://classic.clinicaltrials.gov/ct2/show/NCT01837641</a>	5/3/2013	8/24/2016	Healthy Volunteers or MCI due to Mild/Moderate AD	100	18-above	Phase 1	Completed
<b>Donanemab Healthy Volunteers</b>						<b>66</b>			
<b>Donanemab AD Patients</b>						<b>8033</b>			
<b>Donanemab Total</b>						<b>8099</b>			

**Aduhelm/aducanumab/BIB037**

Investigator ID	#	Link	Study Start Date	Study Completion Date	Population	# participants	Range	Phase	Recruitment Status
221AD305	NCT05310071	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05310071">https://classic.clinicaltrials.gov/ct2/show/NCT05310071</a>	6/2/2022	10/31/2026	Early AD	1512	60-85	Phase 3b/4	Recruiting
221AD304	NCT04241068	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT04241068">https://classic.clinicaltrials.gov/ct2/show/NCT04241068</a>	5/2/2020	2/3/2025	ENROLLS PRIOR ADUCANUMAB RECIPIENTS	1696	50-90	Phase 3b	Active, Not Recruiting
221HV104	NCT05216887	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05216887">https://classic.clinicaltrials.gov/ct2/show/NCT05216887</a>	2/1/2022	7/27/2022	Healthy Volunteers	123	40-70	Phase 1	Completed
221HV103	NCT04924140	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT04924140">https://classic.clinicaltrials.gov/ct2/show/NCT04924140</a>	6/30/2021	10/1/2021	Healthy Volunteers	30	40-70	Phase 1	Completed
221AD301	NCT02477800	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT02477800">https://classic.clinicaltrials.gov/ct2/show/NCT02477800</a>	8/13/2015	8/8/2019	Early AD	1653	50-85	Phase 3	Terminated
221AD302	NCT02484547	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT02484547">https://classic.clinicaltrials.gov/ct2/show/NCT02484547</a>	9/15/2015	8/5/2019	Early AD	1643	50-85	Phase 3	Terminated
221AD103	NCT01677572	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT01677572">https://classic.clinicaltrials.gov/ct2/show/NCT01677572</a>	10/5/2012	7/31/2019	Prodromal or Mild AD	197	50-90	Phase 1	Completed
221AD205	NCT03639987	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT03639987">https://classic.clinicaltrials.gov/ct2/show/NCT03639987</a>	12/20/2018	7/30/2019	MCI due to AD or Mild ADD	52	50-85	Phase 2	Terminated
221AD104	NCT02434718	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT02434718">https://classic.clinicaltrials.gov/ct2/show/NCT02434718</a>	6/24/2015	12/9/2016	Mild to Moderate AD	21	55-85	Phase 1	Completed
221HV102	NCT02782975	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT02782975">https://classic.clinicaltrials.gov/ct2/show/NCT02782975</a>	5/1/2016	11/1/2016	Healthy Volunteers	28	18-55	Phase 1	Completed
221AD101	NCT01397539	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT01397539">https://classic.clinicaltrials.gov/ct2/show/NCT01397539</a>	6/1/2011	8/1/2013	Mild to Moderate AD	53	55-85	Phase 1	Completed
<b>Aducanumab Healthy Volunteers</b>						<b>181</b>			
<b>Aducanumab AD Patients</b>						<b>5131</b>			
<b>Aducanumab Total</b>						<b>5312</b>			

**As of June 2023, total # of individuals with some form of AD that have received or are being actively recruited to receive lecanemab/aducanumab/donanemab 17,600**

**Total individuals that have received lecanemab/aducanumab/donanemab in clinical studies 18,067**